Windlas Biotech Share Price
Sector: Biotechnology & Drugs
891.10 -2.90 (-0.32%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
876.90
Today’s High
900.75
52 Week Low
656.25
52 Week High
1197.00
892.30 -2.80 (-0.31%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
871.90
Today’s High
902.20
52 Week Low
659.00
52 Week High
1198.25
Key Metrics
- Market Cap (In Cr) 1863.15
- Beta 0.74
- Div. Yield (%) 0.65
- P/B 3.7
- TTM P/E 35.66
- Peg Ratio 1.96
- Sector P/E 0
- D/E 0
- Open Price 895.1
- Prev Close 894
Windlas Biotech Analysis
Price Analysis
-
1 Week1.84%
-
3 Months-14.31%
-
6 Month-14.65%
-
YTD-14.03%
-
1 Year26.48%
Risk Meter
- 57% Low risk
- 57% Moderate risk
- 57% Balanced Risk
- 57% High risk
- 57% Extreme risk
Windlas Biotech News
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 27 Mar 2025Breakout stocks to buy: Sumeet Bagadia recommends five shares to buy today
2 min read . 14 Nov 2024Windlas Biotech Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 759.88
- Selling/ General/ Admin Expenses Total
- 122.92
- Depreciation/ Amortization
- 27.99
- Other Operating Expenses Total
- 71
- Total Operating Expense
- 693.76
- Operating Income
- 66.12
- Net Income Before Taxes
- 79.76
- Net Income
- 60.99
- Diluted Normalized EPS
- 28.87
- Period
- 2025
- Total Assets
- 760.45
- Total Liabilities
- 254.68
- Total Equity
- 505.77
- Tangible Book Valueper Share Common Eq
- 238.75
- Period
- 2025
- Cashfrom Operating Activities
- 68.19
- Cashfrom Investing Activities
- -74.06
- Cashfrom Financing Activities
- 1.01
- Net Changein Cash
- -4.86
- Period
- 2024
- Total Revenue
- 630.96
- Selling/ General/ Admin Expenses Total
- 130.01
- Depreciation/ Amortization
- 13.44
- Other Operating Expenses Total
- 2.57
- Total Operating Expense
- 566.23
- Operating Income
- 64.73
- Net Income Before Taxes
- 77.09
- Net Income
- 58.19
- Diluted Normalized EPS
- 27.87
- Period
- 2024
- Total Assets
- 626.21
- Total Liabilities
- 176.25
- Total Equity
- 449.94
- Tangible Book Valueper Share Common Eq
- 214.18
- Period
- 2024
- Cashfrom Operating Activities
- 108.96
- Cashfrom Investing Activities
- -92.07
- Cashfrom Financing Activities
- -15.29
- Net Changein Cash
- 1.6
- Period
- 2023
- Total Revenue
- 513.08
- Selling/ General/ Admin Expenses Total
- 103.66
- Depreciation/ Amortization
- 12.36
- Other Operating Expenses Total
- 1.89
- Total Operating Expense
- 465.22
- Operating Income
- 47.86
- Net Income Before Taxes
- 57.04
- Net Income
- 42.63
- Diluted Normalized EPS
- 19.4
- Period
- 2023
- Total Assets
- 528.98
- Total Liabilities
- 126.7
- Total Equity
- 402.27
- Tangible Book Valueper Share Common Eq
- 191.52
- Period
- 2023
- Cashfrom Operating Activities
- 60.96
- Cashfrom Investing Activities
- -14.11
- Cashfrom Financing Activities
- -43.74
- Net Changein Cash
- 3.12
- Period
- 2022
- Total Revenue
- 465.93
- Selling/ General/ Admin Expenses Total
- 91.07
- Depreciation/ Amortization
- 12.15
- Other Operating Expenses Total
- 2.1
- Total Operating Expense
- 425.65
- Operating Income
- 40.28
- Net Income Before Taxes
- 45.57
- Net Income
- 38.09
- Diluted Normalized EPS
- 18.58
- Period
- 2022
- Total Assets
- 491.01
- Total Liabilities
- 96.23
- Total Equity
- 394.78
- Tangible Book Valueper Share Common Eq
- 180.73
- Period
- 2022
- Cashfrom Operating Activities
- 9.13
- Cashfrom Investing Activities
- -154.58
- Cashfrom Financing Activities
- 130.09
- Net Changein Cash
- -15.36
- Period
- 2021
- Total Revenue
- 427.6
- Selling/ General/ Admin Expenses Total
- 80.06
- Depreciation/ Amortization
- 12.97
- Other Operating Expenses Total
- 1.62
- Total Operating Expense
- 407.21
- Operating Income
- 20.4
- Net Income Before Taxes
- 21.74
- Net Income
- 15.83
- Diluted Normalized EPS
- 14.82
- Period
- 2021
- Total Assets
- 296.12
- Total Liabilities
- 97
- Total Equity
- 199.12
- Tangible Book Valueper Share Common Eq
- 91.14
- Period
- 2021
- Cashfrom Operating Activities
- 17.27
- Cashfrom Investing Activities
- -20.2
- Cashfrom Financing Activities
- 0.78
- Net Changein Cash
- -2.15
- Period
- 2020
- Total Revenue
- 328.85
- Selling/ General/ Admin Expenses Total
- 61.79
- Depreciation/ Amortization
- 9.29
- Other Operating Expenses Total
- 2.04
- Total Operating Expense
- 296.64
- Operating Income
- 32.21
- Net Income Before Taxes
- 24.67
- Net Income
- 16.21
- Diluted Normalized EPS
- 7.44
- Period
- 2020
- Total Assets
- 338.49
- Total Liabilities
- 128.83
- Total Equity
- 209.66
- Tangible Book Valueper Share Common Eq
- 95.95
- Period
- 2020
- Cashfrom Operating Activities
- 24.89
- Cashfrom Investing Activities
- -14.23
- Cashfrom Financing Activities
- -5.44
- Net Changein Cash
- 5.22
- Period
- 2025-03-31
- Total Revenue
- 202.7
- Selling/ General/ Admin Expenses Total
- 31.93
- Depreciation/ Amortization
- 8.33
- Other Operating Expenses Total
- 20.04
- Total Operating Expense
- 185.49
- Operating Income
- 17.21
- Net Income Before Taxes
- 20.82
- Net Income
- 16.28
- Diluted Normalized EPS
- 7.69
- Period
- 2025-03-31
- Total Assets
- 760.45
- Total Liabilities
- 254.68
- Total Equity
- 505.77
- Tangible Book Valueper Share Common Eq
- 238.75
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 68.19
- Cashfrom Investing Activities
- -74.06
- Cashfrom Financing Activities
- 1.01
- Net Changein Cash
- -4.86
- Period
- 2024-12-31
- Total Revenue
- 195.02
- Selling/ General/ Admin Expenses Total
- 32.17
- Depreciation/ Amortization
- 6.94
- Other Operating Expenses Total
- 17.38
- Total Operating Expense
- 177.33
- Operating Income
- 17.69
- Net Income Before Taxes
- 20.34
- Net Income
- 15.58
- Diluted Normalized EPS
- 7.38
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 187
- Selling/ General/ Admin Expenses Total
- 30.97
- Depreciation/ Amortization
- 6.5
- Other Operating Expenses Total
- 16.56
- Total Operating Expense
- 170.45
- Operating Income
- 16.55
- Net Income Before Taxes
- 20.29
- Net Income
- 15.66
- Diluted Normalized EPS
- 7.43
- Period
- 2024-09-30
- Total Assets
- 746.88
- Total Liabilities
- 275.32
- Total Equity
- 471.57
- Tangible Book Valueper Share Common Eq
- 223.3
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 29.66
- Cashfrom Investing Activities
- -37.41
- Cashfrom Financing Activities
- 2.84
- Net Changein Cash
- -4.9
- Period
- 2024-06-30
- Total Revenue
- 175.15
- Selling/ General/ Admin Expenses Total
- 27.85
- Depreciation/ Amortization
- 6.21
- Other Operating Expenses Total
- 17.02
- Total Operating Expense
- 160.48
- Operating Income
- 14.67
- Net Income Before Taxes
- 18.31
- Net Income
- 13.48
- Diluted Normalized EPS
- 6.44
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 171.29
- Selling/ General/ Admin Expenses Total
- 22.85
- Depreciation/ Amortization
- 3.54
- Other Operating Expenses Total
- 19.28
- Total Operating Expense
- 152.82
- Operating Income
- 18.47
- Net Income Before Taxes
- 22.63
- Net Income
- 16.99
- Diluted Normalized EPS
- 8.07
- Period
- 2024-03-31
- Total Assets
- 626.21
- Total Liabilities
- 176.27
- Total Equity
- 449.94
- Tangible Book Valueper Share Common Eq
- 214.18
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 108.96
- Cashfrom Investing Activities
- -92.07
- Cashfrom Financing Activities
- -15.29
- Net Changein Cash
- 1.6
- Period
- 2023-12-31
- Total Revenue
- 162.21
- Selling/ General/ Admin Expenses Total
- 22.73
- Depreciation/ Amortization
- 3.39
- Other Operating Expenses Total
- 17.5
- Total Operating Expense
- 145.27
- Operating Income
- 16.95
- Net Income Before Taxes
- 19.81
- Net Income
- 15.1
- Diluted Normalized EPS
- 7.26
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Windlas Biotech Technical
Moving Average
SMA
- 5 Day888.47
- 10 Day904.6
- 20 Day911.56
- 50 Day956.7
- 100 Day933.47
- 300 Day958.35
Windlas Biotech Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Amrutanjan Health Care
- 735.35
- 7.5
- 1.03
- 861.4
- 548.05
- 2140.7
- Vimta Labs
- 438
- -16.25
- -3.58
- 591.5
- 233.25
- 1954.73
- Windlas Biotech
- 891.1
- -2.9
- -0.32
- 1197
- 656.25
- 1863.15
- Syncom Formulations (india)
- 19.26
- 0.02
- 0.1
- 27.94
- 12.31
- 1795.51
- Ttk Health Care
- 1281.5
- 8.3
- 0.65
- 1923
- 991
- 1810.8
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Amrutanjan Health Care
- 41.65
- 6.48
- 20.26
- 13.26
- Vimta Labs
- 31.61
- 5.49
- 17.42
- 15.73
- Windlas Biotech
- 31.41
- 3.75
- 11.96
- 7.7
- Syncom Formulations (india)
- 34.09
- 5.34
- 12
- 10.15
- Ttk Health Care
- 25.48
- 1.7
- 7.56
- 7.29
Windlas Biotech Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 22-May-25
- Audited Results & Final Dividend
- 11-Feb-25
- Quarterly Results
- 12-Nov-24
- Quarterly Results
- 13-Aug-24
- Quarterly Results
- 20-May-24
- Audited Results & Dividend
- 08-Feb-24
- Quarterly Results
- 08-Nov-23
- Quarterly Results
- 08-Aug-23
- Quarterly Results
- 05-May-23
- Audited Results & Final Dividend
- 08-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 24-Mar-25
- 19-Feb-25
- POM
- 24-Sept-24
- 02-Sept-24
- AGM
- 04-Aug-24
- 01-Jul-24
- POM
- 12-Sept-23
- 17-Aug-23
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 22-May-25
- -
- -
- 5.8
- 21-May-24
- -
- 17-Sept-24
- 5.5
- 05-May-23
- -
- 05-Sept-23
- 4
- 12-May-22
- -
- 09-Sept-22
- 3.5


